Intracranial hypertension induced by rofecoxib.
Several secondary causes are implicated in the etiology of idiopathic intracranial hypertension. Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). We report a case of intracranial hypertension in a 69-year-old man 3 weeks after the commencement of rofecoxib therapy with reversal of clinical findings on drug withdrawal.
Jacob
Saiju
S
University Hospitals of Leicester, Neurology, Leicester, UK.
Rajabally
Yusuf A
YA
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019586:Intracranial Hypertension / Q000139:chemically induced*; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib